GlassScriptPhysician profile
Jeremy Melander
NPI 1811302623
$460.64
in general payments reported to CMS, 2019-2025
14 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.75 · 2022: $86.98 · 2023: $39.59 · 2024: $128 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $102.09 | 2022-2025 | Grafix Pl, Pico 7, Stravix |
| Pfizer INC. | $69.86 | 2023-2025 | |
| Integra Lifesciences Corporation | $46.09 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Amgen INC. | $46.09 | 2024 | Evenity, Prolia |
| Kerecis Limited | $32.32 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Ethicon US, LLC | $30.99 | 2025 | Stratafix |
| Innovation Technologies INC | $23.55 | 2022 | |
| Solventum Corporation | $21.21 | 2025 | Prevena, Abthera Advance, V.A.C. Veraflo Cleanse Choice |
| Harrow Eye, LLC | $17.14 | 2024 | Iheezo |
| Ultragenyx Pharmaceutical INC. | $15.59 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $14.99 | 2025 | |
| Depuy Synthes Sales INC. | $14.45 | 2024 | Fms |
| Omeros Corporation | $13.75 | 2021 | |
| Rayner Intraocular Lenses Limited | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Melander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.